Mayinglong Pharmaceutical Group Co Ltd (600993) - Total Liabilities
Based on the latest financial reports, Mayinglong Pharmaceutical Group Co Ltd (600993) has total liabilities worth CN¥906.06 Million CNY (≈ $132.59 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Mayinglong Pharmaceutical Group Co Ltd (600993) investment intensity to see how much of total assets are deployed in long-term investments.
Mayinglong Pharmaceutical Group Co Ltd - Total Liabilities Trend (2001–2025)
This chart illustrates how Mayinglong Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Mayinglong Pharmaceutical Group Co Ltd balance sheet assets.
Mayinglong Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Mayinglong Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Clariane SE
PA:CLARI
|
France | €10.44 Billion |
|
American Superconductor Corporation
NASDAQ:AMSC
|
USA | $189.74 Million |
|
Prosegur
MC:PSG
|
Spain | €3.69 Billion |
|
Vedant Fashions Limited
NSE:MANYAVAR
|
India | Rs8.88 Billion |
|
BlackRock ESG Capital Allocation Trust
NYSE:ECAT
|
USA | $182.33 Million |
|
Wondershare Technology Co Ltd Class A
SHE:300624
|
China | CN¥601.28 Million |
|
Healthcare Services Group Inc
NASDAQ:HCSG
|
USA | $302.01 Million |
|
Zhejiang Guyuelongshan Shaoxing Wine Co Ltd
SHG:600059
|
China | CN¥757.86 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Mayinglong Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Mayinglong Pharmaceutical Group Co Ltd balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mayinglong Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mayinglong Pharmaceutical Group Co Ltd (2001–2025)
The table below shows the annual total liabilities of Mayinglong Pharmaceutical Group Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥921.49 Million ≈ $134.84 Million |
-6.03% |
| 2024-12-31 | CN¥980.66 Million ≈ $143.50 Million |
+2.19% |
| 2023-12-31 | CN¥959.62 Million ≈ $140.42 Million |
-33.30% |
| 2022-12-31 | CN¥1.44 Billion ≈ $210.54 Million |
+77.03% |
| 2021-12-31 | CN¥812.72 Million ≈ $118.93 Million |
-11.65% |
| 2020-12-31 | CN¥919.89 Million ≈ $134.61 Million |
+41.42% |
| 2019-12-31 | CN¥650.49 Million ≈ $95.19 Million |
+13.19% |
| 2018-12-31 | CN¥574.67 Million ≈ $84.09 Million |
+18.98% |
| 2017-12-31 | CN¥482.99 Million ≈ $70.68 Million |
+0.65% |
| 2016-12-31 | CN¥479.88 Million ≈ $70.22 Million |
-8.30% |
| 2015-12-31 | CN¥523.31 Million ≈ $76.58 Million |
+7.48% |
| 2014-12-31 | CN¥486.89 Million ≈ $71.25 Million |
+5.57% |
| 2013-12-31 | CN¥461.22 Million ≈ $67.49 Million |
+12.61% |
| 2012-12-31 | CN¥409.56 Million ≈ $59.93 Million |
+21.28% |
| 2011-12-31 | CN¥337.70 Million ≈ $49.42 Million |
+4.98% |
| 2010-12-31 | CN¥321.68 Million ≈ $47.07 Million |
-16.25% |
| 2009-12-31 | CN¥384.11 Million ≈ $56.21 Million |
+31.79% |
| 2008-12-31 | CN¥291.46 Million ≈ $42.65 Million |
+22.19% |
| 2007-12-31 | CN¥238.53 Million ≈ $34.90 Million |
-4.79% |
| 2006-12-31 | CN¥250.53 Million ≈ $36.66 Million |
+42.79% |
| 2005-12-31 | CN¥175.45 Million ≈ $25.67 Million |
+34.20% |
| 2004-12-31 | CN¥130.74 Million ≈ $19.13 Million |
-4.29% |
| 2003-12-31 | CN¥136.61 Million ≈ $19.99 Million |
-13.86% |
| 2002-12-31 | CN¥158.59 Million ≈ $23.21 Million |
+6.52% |
| 2001-12-31 | CN¥148.88 Million ≈ $21.79 Million |
-- |
About Mayinglong Pharmaceutical Group Co Ltd
Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. It operates through three segments: Pharmaceutical Manufacturing; Pharmaceutical Wholesale and Retail; and Medical Services. The company offers functional cosmetics, care products and food, Chinese herbal medicines, and medical devices. It a… Read more